A Phase 3 interventional study of Multivirus (CMV, EBV, AdV)-specific T cells in AdV Infection, EBV Infection and CMV Infection, sponsored by Tobias Feuchtinger. Recruiting at 33 sites in 6 countries. Open to participants aged 2 Months and older. Per ClinicalTrials.gov, last updated 2025-07-18.
Sponsored by Tobias Feuchtinger · Phase 3, Interventional, and Treatment
Haematopoietic stem cell transplantation (HSCT) can expose patients to a transient but marked immunosuppression, during which viral infections are an important cause of morbidity and mortality. Adoptive transfer of virus-specific T cells is an attractive approach to restore protective T-cell immunity in patients with refractory viral infections after allogeneic HSCT. The aim of this Phase III trial is to confirm efficacy of this treatment in children and adults.
For a growing number of patients suffering from various conditions as, e.g., haematological malignancies or diverse genetic disorders, haematopoietic stem cell transplantation (HSCT) or bone marrow transplantation offer the only possible curative options. However, HSCT is associated with three major risks: graft rejection, graft-versus-host disease (GvHD) and opportunistic, mostly viral, infections or reactivations resulting from delayed immune reconstitution. Delayed immune reconstitution, however, often is the direct result of the severe pre-transplantation conditioning treatment and T-cell depletion of the transplant necessary to fight the risks of graft rejection and GvHD. Therefore, the risk for life-threatening opportunistic, mostly viral, infections is increased in post-transplantation patients. The most common infections after HSCT are Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Adenovirus (AdV).
The standard treatment approach for viral infections/reactivations is chemotherapy which shows limited efficacy and does not restore immunity. Therefore, effective new treatment options are required for this condition.
Previous investigations have shown that sufficient T-cell immunity is essential for the control and prevention of viral reactivations and newly occurring infections after HSCT. The infusion of T-cells is therefore a promising new approach to treat immune-comprised patients. However, infusion with unselected T cells is associated with an increased risk for GvHD due to the high content of alloreactive T cells. A very promising approach to minimize this problem is to remove alloreactive T cells and enrich, isolate and purify virus-specific T cells.
This approach has been studied for nearly two decades and the data published up to date indicate that virus-specific T-cell responses after adoptive T-cell transfer protect against virus-related complications post HSCT and restore T-cell immunity, in particular for AdV-, CMV- and EBV-infections. Despite these promising results, virus-specific T-cell transfer is not yet translated into daily clinical practice due to the lack of prospective clinical trials confirming the efficacy of this treatment approach.
The overall goal of this Phase III, double-blind placebo-controlled study is to test efficacy of multivirus-specific T cells to bring this treatment method in clinical routine. Multivirus-specific T cells generated in this study will be directed against all three most common post-HSCT viral infections: AdV, CMV and EBV. Thus, T-cell immunity will be restored to fight and prevent new viral infections.
After an initial screening visit, patients eligible to participate in the study will be treated within 28 days after screening. Patients will be randomized in a 2:1 (treatment: placebo) ratio and receive a single infusion with either multivirus-specific T cells or placebo. Patients will be followed up on the day of treatment, 1 day after and 1, 2, 4, 8 and 15 weeks after treatment. Treatment success will be measured by assessing different parameters including symptoms, quality of life, viral load and T-cell immunity in blood samples.
Patients eligible to participate in this study are adult and paediatric patients who have received allogeneic stem cell transplantation and suffer from new or reactivated EBV, AdV or CMV infection refractory to standard antiviral treatment for two weeks. Patients from the six European countries Germany, Belgium, Netherlands, UK, France and Italy will be enrolled. In total 130 patients plus 19 screening failures are expected to participate in the study.
104 studies on the registry are indexed under Adenoviridae Infections; 32 are open to participants now.
This study's planned enrollment of 149 is above the median of 36 across 80 interventional studies indexed under Adenoviridae Infections.
Browse Adenoviridae Infections studies →This is the only study on the registry with Tobias Feuchtinger as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Female patient who is pregnant or breast-feeding. Female patient of child-bearing potential (i.e. post menarche and not surgically sterilized) or male patient of reproductive potential not willing to use an effective method of birth control from Screening until the last follow-up visit (FU6, Visit 8).
Note: Women of childbearing potential must have a negative serum pregnancy test at study entry ≤7 days before IMP administration on Day 0. Acceptable birth control methods are hormonal oral contraceptive ('pill'), contraceptive injection or patch, intrauterine pessar or the combination of two barrier methods. The combination of female and male condomes is NOT acceptable. If the male partner is sterilized, no further contraceptive is required. Women of post-menopausal status (no menses for 12 months without an alternative medical cause) are also not required to use contraceptives during the study.
Allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of Cytomegalovirus, Adenovirus and Epstein-Barr Virus Max dose: * HLA-matched (8/8) donors: 1.0 x 10e5 T cells/kg recipient BW * HLA-mismatched donors: 2.5 x 10e4 T cells/kg recipient BW Min. dose: \- 10 T cells/kg recipient BW
Other: Multivirus (CMV, EBV, AdV)-specific T cells
Suspension of multivirus-specific T cells in 20 mL of 0.9% NaCl + 0.5% HSA
Other: Multivirus (CMV, EBV, AdV)-specific T cells
Cell therapy product which is individually produced for each patient and administered via IV bolus injection.
Viral clearance
Percentage of patients with viral clearance (defined as two consecutive negative PCRs) to determine efficacy of multispecific T-cell transfer in patients with chemo-refractory viral infections after allogeneic stem cell transplantation
Time frame: 8 weeks after treatment
Disease Progression
Percentage of patients with progression between Day 7 and Week 8 after T-cell Transfer to determine efficacy of multispecific T-cell transfer in patients with chemo-refractory viral infections after allogeneic stem cell transplantation
Time frame: day 7 until week 8 after treatment
Incidence of acute GvHD
Incidence of newly occurring acute GvHD grade I from Day 0 to Week 8 and Week 15.
Time frame: 15 weeks after treatment
Incidence of chronic GvHD
Incidence of chronic GvHD from Day 7 to Week 8 and to Week 15 after treatment.
Time frame: 15 weeks after treatment
Time to newly occuring GvHD
Time to newly occurring acute and chronic GvHD.
Time frame: 15 weeks after treatment
Severity of GvHD
Severity of acute GvHD ≥ grade II until Week 8 and Week 15.
Time frame: week 8 and 15 week after treatment
Incidence of acute toxicity
Acute maximum toxicity on the day of T-cell transfer evaluated by measuring vital signs prior to and at different times after the T-cell transfer from 1 hour prior to T-cell transfer to 4 hours post infusion.
Time frame: 15 minutes, 30 minutes, 2 hours and 4 hours post T-cell/placebo transfer
Severity of acute toxicity
Monitoring of adverse events infusion.
Time frame: 15 minutes, 30 minutes, 2 hours and 4 hours post T-cell/placebo transfer
Change in viral load of underlying viral infection
Change in viral load of underlying viral infection as assessed by quantitative PCR analysis of peripheral blood; samples taken weekly from Day 7 to Week 8 after IMP transfer as compared to samples taken at Day 0.
Time frame: 8 weeks after treatment
Time to viral load change of underlying viral infection
Time to 1 log change in viral load.
Time frame: 15 weeks after treatment
Percentage of viral decrease
Percentage of patients with ≥1 log decrease in CMV, EBV or AdV viral load at Week 8.
Time frame: 8 weeks after treatment
Viral reactivations
Number of reactivations of the underlying viral infection following initial viral clearance until end of follow-up.
Time frame: 15 weeks after treatment
Clinical response/resolution of symptoms of underlying viral infection
Number of patients with reduction or clearance of clinical symptoms of underlyingviral infection from Day 7 to Week 8 after IMP transfer as compared to Day 0.
Time frame: 8 weeks after treatment
Overall survival
Overall survival rate (OS): From Day 0 to end of follow-up.
Time frame: 15 weeks after treatment
Necessity of antiviral chemotherapy
Number of days requiring antiviral chemotherapy after T-cell transfer from Day 7 to Week 8 after T-cell transfer.
Time frame: Day 7 until Week 8
Duration of antiviral chemotherapy
Time to last administration of defined antiviral medication or switch to prophylactic treatment from Day 0 to Week 8 after IMP transfer.
Time frame: 8 weeks after treatment
Incidence of viral infections other than underlying viral infection
Number of new viral reactivations (CMV, AdV or EBV) other than the underlying viral infection per patient as assessed by PCR analysis and clinical symptoms throughout the study to evaluate the putative prophylactic effect of the treatment.
Time frame: 15 weeks
Days of hospitalization
Number of days hospitalized after IMP transfer from Day 7 to Week 8.
Time frame: 8 weeks
Life quality in adults
EQ-5D for adult patients (≥18 years) at Screening and Week 8 to evaluate life quality in adults. A scale from 0 to 100 is used with 100 being best value and 0 the worst.
Time frame: Screening and Week 8.
Life quality in adults
FACT-BMT for adult patients (≥18 years) at Screening and Week 8 to evaluate life quality in adults. The patients have to answer questions about their physicial, social, emotional and functional wellbeing. A scale from 0 to 4 is used with 0= not at all, 1= a little bit, 2=somewhat, 3=quite a bit, 4=very much.
Time frame: Screening and Week 8
Life quality in children
PEDS-QL for paediatric patients (\<18 years) at Screening and Week 8 to evaluate life quality in children. The patients and /or their parents have to answer questions about pain and hurt, fatigue and sleep, nausea, worry, Nutrition, thinking and communication. A scale from 0 to 4 is used with 0=never a Problem, 1=almost never a problem, 2= sometimes a problem, 3=often a problem, 4= almost always a problem.
Time frame: Screening and Week 8
Effect on the patient's T-cell phenotype in vivo
T-cell phenotyping, samples taken at Screening, Day 0 and each visit from Day 7 to Week 15 after treatment.
Time frame: Screening until Week 15
Effect on the patient's number of expanded T cells
Analysis of virus-specific T cells: frequencies of in vivo expanded virus-specific T cells in peripheral blood samples taken at Screening, Day 0, Day 7 to Week 15 after treatment.
Time frame: Screening until Week 15
Quality of the IMP and performance of the CliniMACS® Prodigy
Assessment of the cellular composition, in particular the percentage of IFN-gamma+ cells, in the IMP.
Time frame: Before IMP release (between Screening and Day 0)
Evaluation of the drop-out rate
Drop-out rate at Day 0 and reasons for drop-out.
Time frame: at Day 0 (planned treatment day)
Time from inclusion to administration of the IMP
Number of days from Screening to Day 0 (day of IMP transfer) to evaluate the required time frame.
Time frame: Screening until Day 0 (treatment day)
Adverse events
Documentation of incidence, severity and type of adverse events from Day 0 to Week 8 and serious adverse events throughout the study to evaluate safety.
Time frame: 15 weeks
Physical examination
Physical examinations will be conducted to identify possible clinically significant pathologies. These findings will be recorded at each visit. The Karnofsky/Lansky index will be included in the physical examination at Screening and at Week 8 only.
Time frame: Screening to Week 8
Vital Sign - blood pressure
supine systolic and diastolic blood preasure in mm Hg
Time frame: Screening to Week 8
Vital Signs - heart rate
The resting heart rate in beats/min
Time frame: Screening to Week 8
Vital Signs - body temperature
Body temperature in °C (aural)
Time frame: Screening to Week 8
Vital Signs - body weight
body weight in kg
Time frame: Screening to Week 8
Vital Signs - respiratory rate
respiratory rate in breaths/min.
Time frame: Screening to Week 8
Incidence of abnormal laboratory values
haemoglobin, leukocytes, thrombocytes, dirfferential blood count (neutrophil granulocytes, lymphocytes, monocytes and easinophil granulocytes), total and conjugated Bilirubin, C reactive Protein (CRP), creatinine, Alanin aminotransferase (ALT), Aspartate aminotransferase (AST), Gamma glutamyl Transferase (GGT), Lactate Dehydrase (LDH), Urea. A list of normal ranges will be provided from each site.
Time frame: Screening to Week 8
Concomitant medication until Week 8
All concomitant medication will be recorded from Screening until Week 8. The generic name, indication, route of administration, dose/ unit, start and stop date or ongoing, way of application will be documented.
Time frame: 8 weeks after treatment
Concomitant medication until Week 15
During follow-up Week 15, only antiviral therapy, immunosuppression and SAE-related concomitant medication as well as chemotherapy will be documented. The generic name, indication, route of administration, dose/ unit, start and stop date or ongoing, way of application will be documented. Cellular treatment also has to be documented as concomitant medication.
Time frame: 15 weeks after treatment
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.